Back to News
Market Impact: 0.28
Sandoz Partners With MAbxience On Hemophilia Biosimilar Program
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Sandoz announced a licensing, development, manufacturing and commercialization agreement with mAbxience to develop a proposed biosimilar version of emicizumab. The deal expands Sandoz's biosimilar pipeline into hemophilia for the first time, creating a potential new growth opportunity in a specialized treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
SDZ0.58
More News
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- Flock Offers Employees Buyouts as Customers Flee
- Anthropic’s first embedded evaluator is … Accenture?
- Volkswagen and Porsche Holding cut outlook
- Warren Buffett steps down as Berkshire Hathaway chairman
- Meet Warren Buffett’s son Howard, a former sheriff, war photographer, and now, Berkshire’s new chairman